The primary purpose of this study is to estimate the relative bioavailability and food effect of a PF-03882845 tablet as compared to a suspension formulation used in previous clinical studies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
Pfizer Investigational Site
Brussels, Belgium
PF-03882845 PK: Cmax, AUCinf, AUClast, Tmax, t1/2, as data permit.
Post dose is measured at 24, 48 and 96 hours after dose.
Time frame: predose and post each dose (24, 48 and 96 hour timepoints)
Safety: Safety labs, vital signs, ECGs, physical examinations and adverse event monitoring.
Time frame: 45 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.